According to data presented at EADV, at week 16 of the phase 2 study, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI 75 across doses, compared with 9.1% to 19.9% with placebo.
|Articles|January 3, 2018
Clinical Advances in Rosacea Treatment
Advertisement
Clinical Advances in Rosacea Treatment
Dermatology times Video Supplement Podcasts Related Articles
Video:
Specifically engineered for once-daily, non-antibiotic treatment of the inflammatory lesions of rosacea.
Supplement:
Best Practices in the Treatment of Rosacea
In this Dermatology Times supplement, a group of experts in the management and treatment of rosacea discuss the clinical impact of the latest findings regarding understanding of the pathophysiology of the disease, as well as commonly-used therapeutic agents and drug combinations that may be effective in treatment-specific rosacea symptoms.
Learning objectives:
- Discuss new insights regarding the pathophysiology of rosacea, as well as genetic predisposing factors that have been linked to its development
- Assess opportunities to incorporate rosacea phenotyping into the treatment plan for patients presenting with various signs and symptoms
- Determine effective techniques to present appropriate short- and long-term treatment goals for patients with rosacea
- Analyze situations in which the use of low-dose doxycycline would be most appropriate in the treatment of rosacea
Download Supplement
Related Articles:
Lisette Hilton
Links shown between rosacea, other diseases
Lisette Hilton
Rosacea and gastro disorders possibly related
Lisette Hilton
Updated guidelines for diagnosis, treatment of rosacea
John Jesitus
Factors in rosacea pathogenesis clearer
Advertisement
Related to this article
AbbVie reports F-VASI 75 of 55.1% in Viti-Up-1 and 47.4% in Viti-Up-2 at week 76 among patients continuing upadacitinib, with numerically higher responses alongside NB-UVB.
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.
Up to 72% of tulisokibart-treated patients achieved HiSCR50 at week 16 vs 35% with placebo, the first positive phase 2 anti-TL1A data in dermatology.
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Day 1 of EADV 2026 brought new data across atopic dermatitis, cutaneous lupus, skin cancer, AI, climate-related skin disease, and more.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
2
NEA Report Highlights Atopic Dermatitis Care Access Gaps by State
3
Nemolizumab Sustains Atopic Dermatitis Responses Through 3 Years in ARCADIA
4
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
5